# ClinicalTrials.gov record NCT02553603

> PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct02553603-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-11-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02553603-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02553603-tesamorelin-v1.json
- Content SHA-256: `92d0fb4699f57437b32158f82e65693a9da8ebc8b638d4110f38cbde19360c9b`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02553603 ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

## Sources

<a id="source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7"></a>
- **ClinicalTrials.gov record NCT02553603 · retained source version 2019-11-04:5440d24f04c76f23b264240c5404a13d24e6c034852e4d1a165b6473665b22cd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02553603) (`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02553603." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02553603-tesamorelin-v1.json SHA-256: 92d0fb4699f57437b32158f82e65693a9da8ebc8b638d4110f38cbde19360c9b.